My daughter has been living with Polycystic Ovary Syndrome (PCOS) for years, which remained undiagnosed for the major part of her struggle. Diagnosed eventually, she was left with no proper treatment plan. This not only affected her physically but the disease took an enormous toll on her mental health, intensifying her depression and anxiety symptoms.

PCOS affects women in ways more than one can imagine. Beyond the obvious fertility issues, PCOS subjects women to weight gain, which is almost impossible to lose even with a healthy lifestyle. Their bodies resist the weight loss efforts they strenuously attempt, which often leads to a vicious cycle of health complications. According to PCOS Awareness Association, PCOS affects one in ten women of childbearing age and it significantly elevates the risk of developing diabetes, ovarian cancer, fatty liver disease and heart failure.

The GLP-1 medications like Ozempic and Mounjaro have proven beneficial for weight loss in women with PCOS but the costs are immensely high, making it a privilege available only to a certain section of the society. By ensuring ODSP and OHIP coverage for these medications, we can open up a new life's path for these women, especially those who cannot afford these medications.

Call upon ODSP and OHIP to include these revolutionary medications in their coverage. This will not just be a response to an immediate medical need, but a firm step towards a healthier, more inclusive society. Sign this petition today, and help us move one step closer to achieving this goal.